Other Information
−Removed: For a discussion regarding the 2020 Inducement Plan, please see Note 10 “Subsequent Events” of the Unaudited Condensed Consolidated Financial Statements included in Item 1 of Part I within this Quarterly Report.
−Removed: Cyclacel Pharmaceuticals, Inc.
−Removed: 2020 Inducement Equity Incentive Plan
−Removed: Form of Stock Option Grant Notice and Stock Option Agreement under the Cyclacel Pharmaceuticals, Inc.
−Removed: 2020 Inducement Equity Incentive Plan
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a) As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
2 unchanged sentences
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: The following materials from Cyclacel Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the period ended September 30, 2020, formatted in XBRL (Extensible Business Reporting Language):
+Added: The following materials from Cyclacel Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the period ended March 31, 2021, formatted in XBRL (Extensible Business Reporting Language):
(i) the Consolidated Statements of Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.
1 unchanged sentence
CYCLACEL PHARMACEUTICALS, INC.
−Removed: November 12, 2020
/s/ Paul McBarron
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.